Advertisement

Topics

Rigel Pharmaceuticals Inc RIGL Financial and Strategic SWOT Analysis Review [Report Updated: 28062017] Prices from USD $125

10:55 EDT 3 Jul 2017 | BioPortfolio Report Blog

Rigel Pharmaceuticals Inc RIGL Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.
Corporate strategy Analyst's summarization of the company's business strategy.
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.

Highlights

Rigel Pharmaceuticals, Inc. Rigel is a clinicalstage biotechnology company that discovers and develops innovative smallmolecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease mechanisms. The company's clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase SYK inhibitor, in various indications. Rigel submitted an NDA to the US FDA for fostamatinib in patients with chronic or persistent immune thrombocytopenia ITP. Fostamatinib is also being developed for autoimmune hemolytic anemia and IgA nephropathy. Rigel is headquartered in South San Francisco, California, the US.

Rigel Pharmaceuticals Inc Key Recent Developments

May 02,2017: Rigel Announces First Quarter 2017 Financial Results and Provides Company Update
Mar 07,2017: Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results
Nov 01,2016: Rigel Announces Third Quarter 2016 Financial Results and Provides Company Update
Oct 07,2016: Rigel Expands Leadership Team in Research and Business Development
Aug 02,2016: Rigel Announces Second Quarter 2016 Financial Results and Provides Portfolio Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Rigel Pharmaceuticals Inc RIGL Financial and Strategic SWOT Analysis Review [Report Updated: 28062017] Prices from USD $125

NEXT ARTICLE

More From BioPortfolio on "Rigel Pharmaceuticals Inc RIGL Financial and Strategic SWOT Analysis Review [Report Updated: 28062017] Prices from USD $125"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...